Payment overview · 2025
General Payments
$1,330.51
60 reported records · 26 companies
Healthcare provider profile · identity verified
John K. Kim, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ANNANDALE, VA · NPI 1053472159
Verified facts
What the public records show
CMS Open Payments records show John K. Kim, M.D. received $1,330.51 in general payments during 2025 across 60 reported records.
Amgen Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Paxlovid by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Ztlido by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $271.47 | 20.4% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $169.12 | 12.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.42 | 7.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.82 | 5.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.06 | 5.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.54 | 5.6% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $56.59 | 4.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.43 | 3.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.34 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.24 | 3.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.36 | 3.1% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.74 | 2.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.97 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.77 | 1.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.72 | 1.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.53 | 1.8% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.16 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.09 | 1.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $22.56 | 1.7% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.06 | 1.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.25 | 1.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.21 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.29 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.07 | 1.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.96 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,330.51 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $271.47 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $144.95 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.88 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $104.42 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.42 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.82 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.06 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $56.59 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.66 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.43 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $24.17 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 82 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 160 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 90 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 400 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 322 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 312 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
400 | 72 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
184 | 120 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
162 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
160 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 87 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
322 | 79 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
71 | 69 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
312 | 76 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
90 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2034 | 672 |
| Lidocaine | Lidocaine | 1576 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 1344 | 416 |
| Donepezil Hcl | Donepezil Hcl | 928 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 905 | 261 |
| Losartan Potassium | Losartan Potassium | 756 | 248 |
| Omeprazole | Omeprazole | 698 | 267 |
| Fluticasone Propionate | Fluticasone Propionate | 692 | 243 |
| Vascepa | Icosapent Ethyl | 681 | 145 |
| Montelukast Sodium | Montelukast Sodium | 668 | 204 |
| Celecoxib | Celecoxib | 652 | 187 |
| Gabapentin | Gabapentin | 648 | 167 |
| Famotidine | Famotidine | 626 | 236 |
| Metformin Hcl | Metformin Hcl | 595 | 190 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 576 | 182 |
| Clonazepam | Clonazepam | 568 | 162 |
| Mirtazapine | Mirtazapine | 504 | 121 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 480 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 480 | 166 |
| Metoprolol Succinate | Metoprolol Succinate | 458 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 453 | 164 |
| Linzess | Linaclotide | 400 | 72 |
| Metformin Hcl Er | Metformin Hcl | 383 | 139 |
| Trazodone Hcl | Trazodone Hcl | 381 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 377 | 125 |
| Diclofenac Sodium | Diclofenac Sodium | 346 | 84 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 322 | 79 |
| Ztlido | Lidocaine | 312 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 299 | 110 |
| Hydralazine Hcl | Hydralazine Hcl | 293 | 59 |
| Glimepiride | Glimepiride | 271 | 84 |
| Simvastatin | Simvastatin | 268 | 86 |
| Oxycodone Hcl | Oxycodone Hcl | 266 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 254 | 196 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 239 | 153 |
| Pioglitazone Hcl | Pioglitazone Hcl | 237 | 87 |
| Nebivolol Hcl | Nebivolol Hcl | 236 | 60 |
| Alprazolam | Alprazolam | 226 | 60 |
| Memantine Hcl | Memantine Hcl | 226 | 53 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 215 | 69 |
| Jardiance | Empagliflozin | 211 | 87 |
| Lisinopril | Lisinopril | 211 | 72 |
| Prednisone | Prednisone | 207 | 147 |
| Tramadol Hcl | Tramadol Hcl | 205 | 84 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 204 | 59 |
| Alendronate Sodium | Alendronate Sodium | 197 | 63 |
| Furosemide | Furosemide | 195 | 57 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 194 | 143 |
| Carvedilol | Carvedilol | 188 | 46 |
| Finasteride | Finasteride | 185 | 63 |
| Prolia | Denosumab | 184 | 120 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 57 |
| Eliquis | Apixaban | 175 | 50 |
| Pregabalin | Pregabalin | 174 | 46 |
| Ketoconazole | Ketoconazole | 170 | 57 |
| Azithromycin | Azithromycin | 168 | 137 |
| Meloxicam | Meloxicam | 168 | 60 |
| Potassium Chloride | Potassium Chloride | 165 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 163 | 50 |
| Myrbetriq | Mirabegron | 162 | 44 |
| Farxiga | Dapagliflozin Propanediol | 160 | 45 |
| Ibandronate Sodium | Ibandronate Sodium | 160 | 59 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 143 | 42 |
| Lorazepam | Lorazepam | 140 | 38 |
| Mupirocin | Mupirocin | 138 | 90 |
| Tradjenta | Linagliptin | 138 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 134 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 45 |
| Januvia | Sitagliptin Phosphate | 128 | 40 |
| Hydrocortisone | Hydrocortisone | 126 | 40 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 123 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 122 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 39 |
| Glipizide | Glipizide | 118 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 102 |
| Azelastine Hcl | Azelastine Hcl | 110 | 40 |
| Baclofen | Baclofen | 109 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 107 | 29 |
| Metoclopramide Hcl | Metoclopramide Hcl | 106 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 17 |
| Allopurinol | Allopurinol | 104 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 36 |
| Valacyclovir | Valacyclovir Hcl | 104 | 80 |
| Sertraline Hcl | Sertraline Hcl | 102 | 34 |
| Spironolactone | Spironolactone | 100 | 30 |
| Sucralfate | Sucralfate | 100 | 31 |
| Memantine Hcl Er | Memantine Hcl | 93 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 25 |
| Meclizine Hcl | Meclizine Hcl | 91 | 38 |
| Ozempic | Semaglutide | 91 | 20 |
| Gemtesa | Vibegron | 90 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 82 | 55 |
| Creon | Lipase/Protease/Amylase | 82 | 20 |
| Diazepam | Diazepam | 82 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 19 |
| Restasis | Cyclosporine | 79 | 16 |
| Fenofibrate | Fenofibrate | 78 | 20 |
| Fluocinonide | Fluocinonide | 78 | 44 |
| Lovastatin | Lovastatin | 78 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 29 |
| Valsartan | Valsartan | 77 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 76 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 74 | 20 |
| Ondansetron Odt | Ondansetron | 73 | 46 |
| Paxlovid | Nirmatrelvir/Ritonavir | 71 | 69 |
| Icosapent Ethyl | Icosapent Ethyl | 69 | 56 |
| Humalog Kwikpen U-100 | Insulin Lispro | 67 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 21 |
| Ezetimibe | Ezetimibe | 65 | 23 |
| Irbesartan | Irbesartan | 65 | 20 |
| Megestrol Acetate | Megestrol Acetate | 61 | 28 |
| Morphine Sulfate Er | Morphine Sulfate | 60 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 57 | 21 |
| Glipizide Er | Glipizide | 56 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 53 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 16 |
| Colchicine | Colchicine | 52 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 16 |
| Ibuprofen | Ibuprofen | 51 | 32 |
| Xarelto | Rivaroxaban | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Ammonium Lactate | Ammonium Lactate | 48 | 12 |
| Cephalexin | Cephalexin | 48 | 41 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 48 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 16 |
| Lubiprostone | Lubiprostone | 47 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 16 |
| Xiidra | Lifitegrast | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Atenolol | Atenolol | 41 | 13 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Topiramate | Topiramate | 40 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 39 | 13 |
| Amoxicillin | Amoxicillin | 38 | 26 |
| Ciclopirox | Ciclopirox | 37 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | 14 |
| Jublia | Efinaconazole | 36 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 35 | 35 |
| Eszopiclone | Eszopiclone | 35 | 14 |
| Minoxidil | Minoxidil | 35 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Lactulose | Lactulose | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Temazepam | Temazepam | 29 | suppressed |
| Terconazole | Terconazole | 29 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | suppressed |
| Tobramycin | Tobramycin | 26 | 24 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Metronidazole | Metronidazole | 24 | 14 |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | 13 |
| Santyl | Collagenase Clostridium Hist. | 24 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Denta 5000 Plus | Fluoride (Sodium) | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Naproxen | Naproxen | 22 | 11 |
| Pentips Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Neupro | Rotigotine | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Licart | Diclofenac Epolamine | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 13 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,330.51 · 60 records | Amgen Inc. | ABRYSVO, APTIMA, AREXVY, COMIRNATY, CREON, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INTELLIS ADAPTIVESTIM, JARDIANCE, JOURNAVX, Kerendia, LEQEMBI, LINZESS, MOUNJARO, MYFEMBREE, NP Thyroid 60, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UNITHROID, VOQUEZNA, VRAYLAR, Veozah, ZENPEP, ZEPBOUND, ZTLido | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error